

9705392-0



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07F 9/6509, A61K 31/675, C07D 241/44		A1	(11) International Publication Number: WO 97/03079
			(43) International Publication Date: 30 January 1997 (30.01.97)
(21) International Application Number: PCT/EP96/02866 (22) International Filing Date: 1 July 1996 (01.07.96) (30) Priority Data: 2009/95 10 July 1995 (10.07.95) CH (71) Applicant (for all designated States except US): CIBA-GEIGY AG [CH/CH]; Klybeckstrasse 141, CH-4002 Basle (CH). (72) Inventors; and (75) Inventors/Applicants (for US only): MORETTI, Robert [CH/CH]; 393, Chantemerle, CH-1627 Vaulruz (CH). ALLGEIER, Hans [DE/DE]; Lichsenweg 20, D-79541 Lörrach (DE). (74) Common Representative: CIBA-GEIGY AG; Patentabteilung, Klybeckstrasse 141, CH-4002 Basle (CH).		(81) Designated States: AL, AU, BE, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SE, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: NOVEL QUINOXALINE- AND QUINOXALINYLLALKANE-PHOSPHONIC ACIDS			
(57) Abstract			
Quinoxaline- and quinoxalinyllalkane-phosphonic acids of formula (I), wherein R₁ is free or esterified carboxy or free or partially esterified phosphono, R₂ and R₃ are each independently of the other hydrogen or an aliphatic radical, the radicals R₄, R₅ and R₆ are each independently of the others hydrogen, an aliphatic hydrocarbon radical, free or etherified hydroxy, free or etherified mercapto or oxidised free or etherified mercapto, unsubstituted or aliphatically substituted amino, nitro, free or esterified or amidated carboxy, cyano, free or amidated sulfamoyl, halogen or trifluoromethyl and X is a divalent aliphatic radical, and their tautomers and/or salts have NMDA-antagonistic properties and can be used in the treatment of pathological conditions that are responsive to blocking of NMDA-sensitive receptors.			
		(I)	